Abstract
BackgroundDual antiplatelet therapy (DAPT) is the standard care following presentation with an acute coronary syndrome (ACS), but there remains debate regarding the relative benefits of the available P2Y12 receptor antagonists...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
